ClinicalTrials.gg
Status unknownNCT02976012LASERLESSUpdated Nov 29, 2016

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

A Phase 1/2 interventional study of Aflibercept and Endolaserless Vitrectomy in Proliferative Diabetic Retinopathy, sponsored by Southeast Retina Center, Georgia. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-29.

Sponsored by Southeast Retina Center, Georgia · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days but >7 days prior to vitrectomy and one intraoperative IAI at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).

Read the detailed description

This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days but >7 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).

Follow-up visits occur 1 day and 1-2 weeks, and 4 weeks postoperatively and then every 4 weeks from the first postoperative IAI for 52 weeks. One preoperative visit and every postoperative visit (except day one postoperatively) will include ETDRS Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP) measurement, Slit lamp biomicroscopy, Indirect ophthalmoscopy, Heidelberg Spectralis Spectral Domain Optical Coherence Tomography (SD-OCT) (no OCT for preoperative visit) and evaluation for systemic and ocular adverse events. Seven standard field photographs and Optos wide-field fluorescein angiography will be performed at postoperative visits at 4, 16, 28, 40,and 52 weeks. Humphrey visual field (HVF) testing (30-2 and 60-4 test patterns) will be performed at postoperative visits at 4 and 52 weeks. Preoperative B scan echography will be required standard of care(SOC) to assess for macular traction, non-macular traction, retinal detachment and vitreous hemorrhage(VH). Identification of traction macular detachment will exclude the patient from the study.

02

Conditions studied

  • Proliferative Diabetic Retinopathy

Browse trials for

Keywords

  • Proliferative Diabetic Retinopathy
  • Aflibercept
  • Vitreous Hemorrhage
03

In context

Vitreous Hemorrhage

44 studies on the registry are indexed under Vitreous Hemorrhage; 4 are open to participants now.

This study's planned enrollment of 24 is below the median of 56 across 34 interventional studies indexed under Vitreous Hemorrhage.

Browse Vitreous Hemorrhage studies →

Lead sponsor

Southeast Retina Center, Georgia is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults age >18 years with Diabetes Mellitus
  2. PDR- related vitreous hemorrhage and not of another cause
  3. BCVA Vision LP or better
  4. Investigator determination that vitrectomy indicated for PDR-related vitreous hemorrhage
  5. Willing and able to comply with clinic visits and study-related procedures
  6. Provide HIPPA and signed prior to any study procedures

Exclusion criteria

Exclusion Criteria:

  1. A condition per investigator opinion, would preclude participation in the study (unstable medical status, cardiovascular disease, glycemic control, inability to follow up etc.)
  2. Participation in an trial within 30 days of enrollment
  3. Known allergy to IAI
  4. Systemic anti-VEGF or pro-VEGF treatment within 4 months of enrollment
  5. For women of childbearing age, pregnant or lactating or intending to become pregnant within the next 3 years
  6. History of PRP or peripheral retinal cryopexy or peripheral retinopexy for any reason in the study eye
  7. History of vitrectomy in the study eye
  8. History or evidence for rhegmatogenous retinal detachment in the study eye
  9. Evidence of traction retinal detachment involving or threatening central macula in the study eye
  10. Exam evident of external ocular infection (i.e. conjunctivitis, significant blepharitis, chalazion etc)
  11. Intravitreal anti-VEGF injection in the study eye \<4weeks from enrollment.
  12. Pregnant or breast-feeding women
  13. Sexually active men* or women of ** who are unwilling to practice adequate during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. ** women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    IAI q8 week Group

    Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group ("q8 week Group") where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment

    Drug: Aflibercept · Procedure: Endolaserless Vitrectomy

  • Active comparator
    IAI q16 week Group

    Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.

    Drug: Aflibercept · Procedure: Endolaserless Vitrectomy

Interventions

  • . Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.

    Also known as: Eylea, 2 mg/0.05 mL single use vial for intravitreal injection

  • ProcedureEndolaserless Vitrectomy

    Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage

06

What researchers measure

Primary outcomes

  1. • Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:

    Examples include worsened acuity \>30 letters, rhegmatogenous or tractional retinal detachment, endophthalmitis, new or increased vitreous hemorrhage, cataract progression or surgery, need for additional vitrectomy or scleral buckle, development of new DME after OCT documentation of absence of DME, systemic thromboembolic events, deaths and systemic serious adverse events at any time point through week 52.

    Time frame: Through 52 weeks from Baseline

Secondary outcomes

  1. Mean change in BCVA letter score

    Mean change in BCVA letter score over time through week 52

    Time frame: 52 weeks from Baseline

  2. Mean BCVA letter score

    Mean BCVA letter score over time through week 52

    Time frame: 52 weeks from Baseline

  3. Proportion of eyes with progression of PDR

    Proportion of eyes with progression of PDR as defined above at any time point through week 52

    Time frame: Through 52 weeks from Baseline

  4. Mean OCT CSF thickness

    Mean OCT CSF thickness over time through week 52

    Time frame: Through 52 weeks from Baseline

  5. Proportion of eyes with OCT CSF thickness <300um

    Proportion of eyes with OCT CSF thickness \<300um at week 52

    Time frame: Through 52 weeks from Baseline

  6. Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage

    Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage at week 52

    Time frame: Through 52 weeks from Baseline

  7. Proportion of eyes with absence of active neovascularization

    Proportion of eyes with absence of active neovascularization by Optos widefield fluorescein angiography at week 52

    Time frame: Through 52 weeks from Baseline

  8. Proportion of eyes with absence of active neovascularization

    Proportion of eyes with absence of active neovascularization by 7 standard field photography at week 52

    Time frame: Through 52 weeks from Baseline

  9. Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage

    Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage from baseline angiograms at week 52

    Time frame: Through 52 weeks from Baseline

  10. Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization

    Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization from baseline angiograms at week 52

    Time frame: Through 52 weeks from Baseline

  11. Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance

    Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance from baseline photographs at week 52

    Time frame: Through 52 weeks from Baseline

  12. Mean cumulative score and change for the combined 30-2 and 60-4 HVF test

    Mean cumulative score and change for the combined 30-2 and 60-4 HVF test from week 4 to week 52.

    Time frame: Through 52 weeks from Baseline

  13. Proportion of eyes requiring additional IAI other than mandatory injections

    Proportion of eyes requiring additional IAI other than mandatory injections through week 52

    Time frame: Through 52 weeks from Baseline

  14. Proportion of eye with progression of PDR requiring rescue PRP standard of care

    Proportion of eye with progression of PDR requiring rescue PRP standard of care at any time point through 52 weeks

    Time frame: Through 52 weeks from Baseline

  15. Proportion of eyes requiring PRP or retinopexy

    Proportion of eyes requiring PRP or retinopexy through week 52

    Time frame: Through 52 weeks from Baseline

  16. Proportion of eyes requiring additional vitrectomy

    Proportion of eyes requiring additional vitrectomy through week 52

    Time frame: Through 52 weeks from Baseline

  17. Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy

    Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy

    Time frame: Through 52 weeks from Baseline

07

Study locations

1 of 1 sites recruiting
  • Southeast Retina Center, PC
    Augusta, Georgia 30809, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2015
First posted
Nov 29, 2016
Start
Jun 2016
Primary completionEst.
Jun 2018
CompletionEst.
Jun 2018
Last update
Nov 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02976012
Lead sponsor
Southeast Retina Center, Georgia
Responsible party
Dennis M. Marcus, M.D. (Principal Investigator, Southeast Retina Center, Georgia) — Principal investigator
First posted
Nov 29, 2016
Start date
Jun 2016
Primary completion
Jun 2018 (estimated)
Completion
Jun 2018 (estimated)
Last update
Nov 29, 2016

Study contacts

Dennis M Marcus, MD
Contact
dmarcus@southeastretina.com
706-650-0061
Siobhan Ortiz
Contact
siobhan@southeastretina.com
706-650-0061
Dennis M Marcus, MD
principal investigator · Southeast Retina Center, PC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion